Frontier Capital Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-316,134
| Closed | -$21.9M | – | 269 |
|
|
2023
Q3 | $21.9M | Sell |
316,134
-55,889
| -15% | -$4.49M | 0.24% | 143 |
|
|
2023
Q2 | $35.1M | Buy |
372,023
+149,525
| +67% | +$13M | 0.34% | 106 |
|
|
2023
Q1 | $18.4M | Buy |
222,498
+11,424
| +5% | +$898K | 0.19% | 158 |
|
|
2022
Q4 | $15.7M | Sell |
211,074
-7,030
| -3% | -$542K | 0.17% | 171 |
|
|
2022
Q3 | $18M | Sell |
218,104
-9,773
| -4% | -$940K | 0.21% | 152 |
|
|
2022
Q2 | $21.7M | Sell |
227,877
-26,177
| -10% | -$2.71M | 0.25% | 142 |
|
|
2022
Q1 | $29.9M | Sell |
254,054
-39,855
| -14% | -$4.47M | 0.27% | 130 |
|
|
2021
Q4 | $38.1M | Sell |
293,909
-44,255
| -13% | -$5.16M | 0.3% | 119 |
|
|
2021
Q3 | $38.3M | Sell |
338,164
-27,148
| -7% | -$3.1M | 0.3% | 121 |
|
|
2021
Q2 | $37.8M | Buy |
365,312
+85,128
| +30% | +$8.02M | 0.28% | 135 |
|
|
2021
Q1 | $23.4M | Sell |
280,184
-57,606
| -17% | -$4.87M | 0.18% | 161 |
|
|
2020
Q4 | $30.8M | Sell |
337,790
-189,847
| -36% | -$15.7M | 0.23% | 157 |
|
|
2020
Q3 | $42.1M | Sell |
527,637
-149,684
| -22% | -$11.7M | 0.37% | 98 |
|
|
2020
Q2 | $46.8M | Sell |
677,321
-43,795
| -6% | -$3.11M | 0.41% | 86 |
|
|
2020
Q1 | $45.3M | Sell |
721,116
-167,994
| -19% | -$12.1M | 0.51% | 65 |
|
|
2019
Q4 | $69.1M | Sell |
889,110
-107,874
| -11% | -$8.42M | 0.51% | 70 |
|
|
2019
Q3 | $73.1M | Sell |
996,984
-936,777
| -48% | -$65.8M | 0.57% | 55 |
|
|
2019
Q2 | $119M | Sell |
1,933,761
-214,863
| -10% | -$13M | 0.9% | 20 |
|
|
2019
Q1 | $137M | Sell |
2,148,624
-71,823
| -3% | -$4.1M | 0.97% | 14 |
|
|
2018
Q4 | $113M | Sell |
2,220,447
-182,514
| -8% | -$9.23M | 0.92% | 22 |
|
|
2018
Q3 | $139M | Buy |
2,402,961
+109,428
| +5% | +$5.35M | 0.9% | 17 |
|
|
2018
Q2 | $111M | Sell |
2,293,533
-46,920
| -2% | -$2.19M | 0.79% | 31 |
|
|
2018
Q1 | $109M | Buy |
2,340,453
+30,279
| +1% | +$1.31M | 0.79% | 32 |
|
|
2017
Q4 | $86.8M | Sell |
2,310,174
-97,689
| -4% | -$3.59M | 0.63% | 49 |
|
|
2017
Q3 | $87.7M | Buy |
2,407,863
+8,703
| +0.4% | +$332K | 0.63% | 48 |
|
|
2017
Q2 | $94.6M | Sell |
2,399,160
-15,168
| -0.6% | -$554K | 0.69% | 39 |
|
|
2017
Q1 | $75.7M | Sell |
2,414,328
-109,932
| -4% | -$3.44M | 0.56% | 57 |
|
|
2016
Q4 | $78.8M | Buy |
2,524,260
+2,853
| +0.1% | +$92.4K | 0.61% | 49 |
|
|
2016
Q3 | $101M | Buy |
2,521,407
+690,336
| +38% | +$26M | 0.81% | 30 |
|
|
2016
Q2 | $60.9M | Buy |
1,831,071
+924,669
| +102% | +$31.6M | 0.5% | 67 |
|
|
2016
Q1 | $26.7M | Buy |
906,402
+28,032
| +3% | +$773K | 0.21% | 163 |
|
|
2015
Q4 | $23.1M | Sell |
878,370
-1,434
| -0.2% | -$37.2K | 0.19% | 176 |
|
|
2015
Q3 | $20.8M | Buy |
879,804
+300
| +0% | +$7.24K | 0.18% | 185 |
|
|
2015
Q2 | $20.9M | Buy |
879,504
+2,250
| +0.3% | +$50.8K | 0.15% | 205 |
|
|
2015
Q1 | $20.8M | Sell |
877,254
-32,760
| -4% | -$735K | 0.15% | 208 |
|
|
2014
Q4 | $19.3M | Sell |
910,014
-28,716
| -3% | -$577K | 0.14% | 208 |
|
|
2014
Q3 | $16M | Sell |
938,730
-12,630
| -1% | -$199K | 0.13% | 219 |
|
|
2014
Q2 | $13.6M | Sell |
951,360
-55,560
| -6% | -$753K | 0.1% | 234 |
|
|
2014
Q1 | $12.4M | Buy |
1,006,920
+158,040
| +19% | +$1.82M | 0.09% | 246 |
|
|
2013
Q4 | $9.3M | Sell |
848,880
-2,016,402
| -70% | -$22.7M | 0.07% | 260 |
|
|
2013
Q3 | $33.3M | Sell |
2,865,282
-638,400
| -18% | -$7.47M | 0.26% | 135 |
|
|
2013
Q2 | $39.2M | Buy |
+3,503,682
| New | +$41.5M | 0.33% | 109 |
|
Other funds holding EW
Frontier Capital Management's EW Position: Q4 2023 in Review
Frontier Capital Management sold out of Edwards Lifesciences (EW) in Q4 2023, closing a stake of 316,134 shares — an estimated $21.9M sold.
Frontier Capital Management first reported a position in EW in Q2 2013 and held it in 42 quarters. The position peaked at $139M in Q3 2018. 1,245 funds tracked by Wall St. Rank hold EW as of Q4 2023.
- Frontier Capital Management reported no remaining Edwards Lifesciences position as of Q4 2023 after selling out during the quarter.
- Frontier Capital Management sold 316,134 Edwards Lifesciences shares in Q4 2023, an estimated $21.9M.
- Frontier Capital Management first reported a position in Edwards Lifesciences in Q2 2013 and held it in 42 quarters.
- Frontier Capital Management's Edwards Lifesciences position peaked at $139M in Q3 2018.
- 1,245 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2023.
Based on Frontier Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.